Canaccord Genuity Group Reiterates Buy Rating for Voyager Therapeutics (NASDAQ:VYGR)

Canaccord Genuity Group reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report report published on Thursday,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush lowered their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, November 10th. Finally, Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and an average price target of $17.00.

Voyager Therapeutics Trading Down 9.3 %

NASDAQ VYGR opened at $5.64 on Thursday. The firm has a market capitalization of $308.11 million, a P/E ratio of 7.94 and a beta of 0.89. The firm’s fifty day moving average price is $6.62 and its two-hundred day moving average price is $7.49. Voyager Therapeutics has a 1 year low of $5.59 and a 1 year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period last year, the firm earned ($0.59) earnings per share. On average, research analysts anticipate that Voyager Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.53% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in Voyager Therapeutics by 198.6% during the 1st quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after acquiring an additional 32,437 shares during the last quarter. Empowered Funds LLC boosted its holdings in Voyager Therapeutics by 8.2% during the 1st quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock worth $367,000 after acquiring an additional 2,975 shares during the last quarter. ProShare Advisors LLC purchased a new position in Voyager Therapeutics during the 1st quarter worth $101,000. Vanguard Group Inc. boosted its holdings in Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Voyager Therapeutics by 10.1% during the 1st quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock worth $4,280,000 after acquiring an additional 42,029 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.